• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

GABAERGIC DRUGS AS AN ALTERNATIVE TO BENZODIAZEPINES FOR THE TREATMENT OF ANXIETY DISORDERS

anxiety management non-benzodizepine tranquilizers gabaergic drugs pantogam afobazole adaptol grandaxin phenibut picamilon

  • Please log in to reply
6 replies to this topic

#1 112358134

  • Guest
  • 36 posts
  • 4
  • Location:Moscow
  • NO

Posted 05 October 2017 - 12:06 AM


Hey guys!

 

I thought that this post would be appropriate here, as some people are into nootropics and supplements because of anxiety issues. Also, it is a sad thing that there is not much information on these drugs outside of former Soviet Union countries.

 

As of today, anxiety disorders are one of the most common psychological disorders in the world. According to statistical data, about 18% of the population in the United States suffer from anxiety disorders, and many of such people do not receive the needed treatment.

 

The typical treatment for anxiety is Benzodiazepine tranquilizers. They usually act by binding to the benzodiazepine receptor site on the GABA-A receptors. Benzodiazepines have a pronounced anti-anxiety effect, but they also carry significant downsides such as drowsiness, muscle relaxation, cognitive impairments and have an addiction potential.

 

The following article is a review of GABAergic drugs that are mostly used in the former Soviet Union countries. Most of these drugs have nootropic effects and they also have certain potential to be  a good alternative to benzodiazepines.

 

nootropics-pantogam-active-d-l-hopanteni

Pantogam (Hopantenic acid) is a Vitamin B5 derivative with anxiolytic activity. It is used since 1970’s n several countries as a treatment for epilepsy, developmental delays, anxiety disorders and chronic fatigue. Hopanthenic acid acts by interacting with D2 dopamine, GABA-A, and GABA-B receptors. Moreover, it does have pronounced cholinergic action, thus having a positive effect on cognitive functions. Pantogam has a novel racemic modification called “Pantogam Active”, which is marketed since 2008. The modified version has more pronounced anxiolytic and anticonvulsant effect because of the different racemic mixture.

 

nootropics-afobazole-fabomotizole-2_comp

Afobazole (Fabomotizole) is a Russian anxiolytic drug developed in the 2000’s, which was primarily designed and used for anxiety management. Afobazole has a unique mechanism of action. It is not habit-forming, since it has no affinity with GABA receptors. However, Fabomotizole restores the sensitivity of GABA receptors to endogenous ligands. Fabomotizole interacts with Melatonin MT1/MT3 receptors, sigma-1 receptors and has been shown to possess neurotrophic properties.

 

nootropics-adaptol-mebicar-2_compact.png

Adaptol (Mebicar) is an urea derivative with anxiolytic and nootropic action; it is used in medical practice since 1979. The mechanism of action of Mebicar is complex; it appears to have an influence on all major monoamine systems in the brain with moderate cholinergic and anti-excitotoxic effects.One of the most important properties of Adaptol is its low toxicity. Russian medical journal “Psychiatry” reported a case when a patient with schizophrenia took 80 pills of Adaptol (24 grams) daily for two months in his attempt to self-medicate. His subjective well-being remained unchanged and he showed no symptoms of intoxication after a medical examination.
 

grandaxin_2_compact.png?v=1505116277

Grandaxin (Tofisopam) is a benzodiazepine tranquilizer with unique pharmacological atypical for commonly used benzodiazepines. It is used since 1970’s as anxiolytic drug in several countries, mostly Russia and Hungary.  Tofisopam is a 2,3-benzodiazepine derivative, while most widely used BZDs like Lorazepam are 1,4 benzodiazepine derivatives. Because of such structural differences, it has a different mechanism of action. One of the most important benefits of Grandaxin over typical Benzos is the lack of addictive potential. Rather than causing sedation and impairment of cognition, Tofisopam was shown to produce a subtle stimulant effect by increasing the sensitivity of dopamine receptors. It does not bind to benzodiazepine receptors but is able to potentiate the effect of other BZDs.
 
 

nootropics-phenibut-2_compact.png?v=1500

Phenibut (Beta-Phenyl-GABA) was designed in the 1960’s by Soviet scientist as a non-sedating anxiolytic drug. Initially, it was used by astronauts; as of today, Phenibut is widely prescribed by Russian doctors for the treatment of anxiety disorders, chronic fatigue, insomnia and alcohol withdrawal syndrome. Phenibut acts as a GABA-B receptors agonist and it is able to increase dopamine levels in the brain. The drug is highly effective for anxiety, however, it may be habit-forming if used irresponsible and is known for its abuse potential.

 

nootropics-picamilon-nicotinoyl-gaba-2_c

Picamilon (Nicotinoyl GABA) is a derivative of GABA and niacin (Vitamin B3) developed for the needs of Soviet psychiatry.Unlike GABA itself, Picamilon is able to penetrate the blood-brain-barrier and produce an anxiolytic effect. Besides that, the drug has nootropic properties and was shown to improve cerebral blood flow and glucose/oxygen uptake by the brain.

 

nootropics-mexidol-emoxypine-3_compact.p

Mexidol (Emoxypine Succinate) is a Russian antioxidant drug with pronounced nootropic and anxiolytic activity. It is close to pyridoxine (Vitamin B6) by its chemical structure. Since its invention in the 1980’s, Emoxypine is widely used in Russian medicine as a treatment for cerebrovascular disorders, traumatic brain injuries, chronic fatigue, anxiety disorders and alcohol withdrawals. Mexidol is often used recreationally to protect the brain from the toxic effect of alcohol consumption and prevent hangovers. Although this drug does not bind to GABA receptors, it does increase their sensitivity, thus providing an anxiolytic effect. According to studies, a coadministration of Mexidol with Phenazepam in low therapeutic doses provides the same anxiolytic response as Phenazepam alone in 10x higher dose.

 

nootropics-strezam-etifoxine-3_compact.p

Stresam (Etifoxine) is a benzoxazine derivative with anxiolytic action developed in 1966 in Germany. Currently, it is manufactured in France and is used in over 42 countries across the world, mostly in Russia and South Africa. Etifoxine provides anxiolytic effect comparable to that of Lorazepam and Diazepam, without causing adverse effects that are typical for benzodiazepines. Stresam acts by interacting with GABA-A receptors on a different binding site than benzodiazepines. It also stimulates the synthesis of endogenous neurosteroids with anxiolytic activity and has neurotrophic properties. Etifoxine should be taken with caution, as it may cause allergic reactions and can be hepatotoxic.

 

Phenazepam is a benzodiazepine tranquilizer developed in the 1974 in Soviet Union.The drug is widely used in post-soviet states. Its pharmacological action, side effects and indications for use are similar to that of other benzodiazepine drugs. Just as other 1,4-BZDs, Phenazepam has addictive potential. Currently, Phenazepam, Gidazepam, and Tofisopam are the only benzodiazepine derivatives that are not considered as narcotic drugs in Russia.

 

Gidazepam is a benzodiazepine tranquilizer that is currently used as a mild anxiolytic in Ukraine. It appears to have mild antidepressant effect and less severe side effect compared to other benzodiazepines; thus, Gidazepam the official indications for use include neurasthenia which is uncommon for BZDs.

 

The original article can be found here:

 

GABAERGIC DRUGS AS AN ALTERNATIVE TO BENZODIAZEPINES FOR THE TREATMENT OF ANXIETY DISORDERS

 

 

 

 

 

 



#2 112358134

  • Topic Starter
  • Guest
  • 36 posts
  • 4
  • Location:Moscow
  • NO

Posted 05 October 2017 - 12:16 AM

Let me know if you are interested or have any questions :)  I will be working with a physician, who have been prescribing these things, so he might be here to help you in some time.



sponsored ad

  • Advert
Click HERE to rent this advertising spot for BRAIN HEALTH to support LongeCity (this will replace the google ad above).

#3 normalizing

  • Guest
  • 2,692 posts
  • -105
  • Location:Warm Greetings
  • NO

Posted 05 October 2017 - 06:31 AM

laika, that is severe advertisement and promotion of your website to sell these drugs. you should have used the retailer forum for this subject.

 

but while on point, i have to ask, whats the real science behind any of these to threat addictions like benzodiazepine and alcohol addictions? i never saw anything reliable convincing enough, but then again most research is done in russia, so not much to go on there.

 



#4 Daniel Cooper

  • Member, Moderator
  • 2,699 posts
  • 642
  • Location:USA

Posted 05 October 2017 - 06:15 PM

What is the typical dosing schedule for Afobazole?  What is the evidence that it "restores the sensitivity of GABA receptors to endogenous ligands"?

 

 

 

 

 


Edited by Daniel Cooper, 05 October 2017 - 06:16 PM.


#5 tunt01

  • Guest
  • 2,308 posts
  • 414
  • Location:NW

Posted 05 October 2017 - 08:32 PM

GABA and Benzodiazepine are not an area I've spent a lot of time on.   But I noticed when I was looking at Telmisartan and AT1 receptor blockers (ARBs), there was a pretty interesting angle that they inhibited stress and had some kind of interaction with BZ1 receptors.

 

Given that Telmisartan and AT1 blockage should be life extending in a SIRT3/NAMPT mediated behavior (assuming you don't get lung cancer first), it might be worth looking at for those who are interested in this anxiolytic aspect..

 

 

A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding.
Abstract

Long-term pretreatment with an angiotensin II AT1 antagonist blocks angiotensin II effects in brain and peripheral organs and abolishes the sympathoadrenal and hypothalamic-pituitary-adrenal responses to isolation stress. We determined whether AT1 receptors were also important for the stress response of higher regulatory centers. We studied angiotensin II and corticotropin-releasing factor (CRF) receptorsand benzodiazepine binding sites in brains of Wistar Hannover rats. Animals were pretreated for 13 days with vehicle or a central and peripheral AT1 antagonist (candesartan, 0.5 mg/kg/day) via osmotic minipumps followed by 24 h of isolation in metabolic cages, or kept grouped throughout the study (grouped controls). In another study, we determined the influence of a similar treatment with candesartan on performance in an elevated plus-maze. AT1 receptor blockade prevented the isolation-induced increase in brain AT1 receptors and decrease in AT2 binding in the locus coeruleus. AT1 receptor antagonism also prevented the increase in tyrosine hydroxylase mRNA in the locus coeruleus. Pretreatment with the AT1 receptor antagonist completely prevented the decrease in cortical CRF1 receptor and benzodiazepinebinding produced by isolation stress. In addition, pretreatment with candesartan increased the time spent in and the number of entries to open arms of the elevated plus-maze, measure of decreased anxiety. Our results implicate a modulation of upstream neurotransmission processes regulating cortical CRF1 receptors and the GABA(A) complex as molecular mechanisms responsible for the anti-anxiety effect of centrally acting AT1 receptor antagonists. We propose that AT1 receptor antagonists can be considered as compounds with possible therapeutic anti-stress and anti-anxiety properties

 

.

 
Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress.
Abstract

Centrally acting Angiotensin II AT(1) receptor blockers (ARBs) protect from stress-induced disorders and decrease anxiety in a model of inflammatory stress, the systemic injection of bacterial endotoxin lipopolysaccharide (LPS). In order to better understand the anxiolytic effect of ARBs, we treated rats with LPS (50 μg/kg) with or without 3 days of pretreatment with the ARB candesartan (1mg/kg/day), and studied cortical benzodiazepine (BZ) and corticotrophin-releasing factor (CRF) receptors. We compared the cortical BZ and CRF receptorsexpression pattern induced by LPS with that produced in restraint stress. Inflammation stress produced a generalized increase in cortical BZ(1) receptors and reduced mRNA expression of the GABA(A) receptor γ(2) subunit in cingulate cortex; changes were prevented by candesartan pretreatment. Moreover, restraint stress produced similar increases in cortical BZ(1) receptor binding, and candesartan prevented these changes. Treatment with candesartan alone increased cortical BZ(1) binding, and decreased γ(2) subunit mRNA expression in the cingulate cortex. Conversely, we did not find changes in CRF(1) receptor expression in any of the cortical areas studied, either after inflammation or restraint stress. Cortical CRF(2) receptor binding was undetectable, but CRF(2) mRNA expression was decreased by inflammation stress, a change prevented by candesartan. We conclude that stress promotes rapid and widespread changes in cortical BZ(1) receptor expression; and that the stress-induced BZ(1) receptor expression is under the control of AT(1) receptor activity. The results suggest that the anti-anxiety effect of ARBs may be associated with their capacity to regulate stress-induced alterations in cortical BZ(1) receptors.

 

 

 



#6 gamesguru

  • Guest
  • 3,493 posts
  • 432
  • Location:coffeelake.intel.int

Posted 05 October 2017 - 10:50 PM

L-theanine is probably better than anything mentioned above.  but i can see certain personalities disagreeing with me here, with the nerds grabbing afobazole, party animals opting for phenibut, and the soccer moms going with picamilon


  • Disagree x 1

sponsored ad

  • Advert
Click HERE to rent this advertising spot for BRAIN HEALTH to support LongeCity (this will replace the google ad above).

#7 normalizing

  • Guest
  • 2,692 posts
  • -105
  • Location:Warm Greetings
  • NO

Posted 06 October 2017 - 01:16 AM

l theanine is not a drug though so stupid comparison. from personal experience l theanine does nothing for me, i remember dosing few grams too and i thought maybe it might actually be a stimulant for me, not downer which is surprising. i would never recommend l theanine for benzo withdrawal as that is very stupid as one guy on the forum found out







Also tagged with one or more of these keywords: anxiety management, non-benzodizepine tranquilizers, gabaergic drugs, pantogam, afobazole, adaptol, grandaxin, phenibut, picamilon

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users